Valsartan and Vidaza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Valsartan (valsartan) and Vidaza (azacitidine). Common drug interactions include dyspnoea among females and neutrophil count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Valsartan and Vidaza. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Valsartan?

Valsartan has active ingredients of valsartan. It is often used in high blood pressure. eHealthMe is studying from 63,805 Valsartan users. Check the latest studies of Valsartan.

What is Vidaza?

Vidaza has active ingredients of azacitidine. It is often used in myelodysplastic syndrome. eHealthMe is studying from 12,837 Vidaza users. Check the latest studies of Vidaza.

On Jul, 10, 2026

50 people who take Valsartan and Vidaza together, and have interactions are studied.

What are the common drug interactions of Valsartan and Vidaza, by gender? *:

female:

Dyspnoea (difficult or laboured respiration)
Oedema peripheral (superficial swelling)
Febrile neutropenia (fever with reduced white blood cells)
Neutropenia (an abnormally low number of neutrophils)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Cardiac failure
Cellulitis (infection under the skin)
Pneumonia
Sepsis (a severe blood infection that can lead to organ failure and death)
Constipation

male:

Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
White blood cell count decreased
Dyspnoea (difficult or laboured respiration)
Pneumonia
Abdominal pain
Angina pectoris (chest pain due to ischemia of the heart muscle)
Asthenia (weakness)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Decreased appetite
Fatigue (feeling of tiredness)

What are the common drug interactions of Valsartan and Vidaza, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Dyspnoea (difficult or laboured respiration)
White blood cell count decreased
Constipation
Cellulitis (infection under the skin)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Cardiac failure
Cerebral infarction (less blood supply to brain resulting tissue damage)
Injection site rash
Sepsis (a severe blood infection that can lead to organ failure and death)
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 23 people, 46.00%
Constipation: 14 people, 28.00%
Nausea (feeling of having an urge to vomit): 14 people, 28.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 13 people, 26.00%
Depression: 9 people, 18.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 9 people, 18.00%
Pain: 9 people, 18.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 9 people, 18.00%
Tumor Lysis Syndrome: 8 people, 16.00%
Hyperlipidaemia (presence of excess lipids in the blood): 7 people, 14.00%

* Approximation only. Some reports may have incomplete information.

Do you take Valsartan and Vidaza?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously